Merck increases involvement in osteoporosis management
This article was originally published in Clinica
Executive Summary
Merck & Co (US) is to obtain worldwide exclusive rights to CompuMed's bone density test, OsteoGram, which uses computer image analysis of hand X-rays to assess osteoporosis risk. CompuMed will receive a licensing fee and royalties on sales of the test over five years. Specific financial terms have not been disclosed.